Features Partner Sites Information LinkXpress
Sign In
Demo Company

Nanostring Technique Identifies Potential Melanoma Immunotherapy Targets

By BiotechDaily International staff writers
Posted on 23 Sep 2013
Print article
An advanced "nanostring" DNA expression analysis technique detected seven genes that are potential immunotherapy targets for the treatment of melanoma and could increase the number of patients potentially eligible for adoptive immunotherapy.

Nanostring technology is a variation of the DNA microarray that uses molecular "barcodes" and microscopic imaging to detect and count up to several hundred unique transcripts in one hybridization reaction. Each color-coded barcode is attached to a single target-specific probe corresponding to a gene of interest.

Investigators at the [US] National Cancer Institute (Bethesda, MD, USA) designed a nanostring probe set containing 97 genes, 72 of which were considered potential candidate genes for immunotherapy. Five established melanoma cell lines, 59 resected metastatic melanoma tumors, and 31 normal tissue samples were profiled and analyzed using the nanostring technique.

Results published in the September 10, 2013, online edition of the journal Clinical Cancer Research revealed that of the 72 potential target genes, 33 were overexpressed in more than 20% of studied melanoma tumor samples. Twenty of those genes were identified as differentially expressed between normal tissues and tumor samples. Analysis of normal tissue gene expression identified seven genes with limited normal tissue expression that warranted further consideration as potential immunotherapy target antigens: CSAG2, MAGEA3, MAGEC2, IL13RA2, PRAME, CSPG4, and SOX10. These genes were highly overexpressed on a large percentage of the studied tumor samples, with expression in a limited number of normal tissue samples at much lower levels.

“We identified seven potential candidate genes that deserve further consideration as targets for melanoma immunotherapy,” said senior author Dr. Richard Morgan, a researcher in the tumor immunology section of the [US] National Cancer Institute. “We used nanostring technology because it is very robust, yielding quantitative and extremely reproducible results and, in addition, an antigen expression profile can be constructed for a patient from a very small amount of tumor sample, which makes nanostring a better clinical tool.”

“Our laboratory has developed a battery of different antigen receptors to target a wide range of antigens, and we can engineer human immune cells to recognize the targets in patients’ tumors and kill those cells,” said Dr. Morgan. “This is a good example of how newer technologies like nanostring arm cancer researchers and clinicians with the best gear to make tremendous advancements in cancer research and treatment.”

Related Links:
[US] National Cancer Institute

Print article



view channel
Image: A partially completed three-dimensional printed airway from nostril to trachea with fine structure of the nasal cavity showing (Photo courtesy of Dr. Rui Ni, Pennsylvania State University).

The Structure of the Nasal Cavity Channels Food Smells into the Nose and Avoids the Lungs

Three-dimensional printing technology was used to create a model of the nasal cavity that enabled researchers to demonstrate why the smell of food goes into the nose rather than down into the lungs.... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image:  The BioSpa 8 Automated Incubator (Photo courtesy of BioTek Instruments).

Smart Incubator System Automates Live Cell Assay Operations

A new instrument that automates laboratory workflow by linking microplate washers and dispensers with readers and imaging systems is now available for biotech and other life sciences researchers.... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.